MIT-Harvard Center of Cancer Nanotechnology Excellence

麻省理工学院-哈佛大学癌症纳米技术卓越中心

• 批准号: 8136182
• 负责人: ROBERT Samuel LANGER
• 金额: $ 229万
• 依托单位: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8136182
• 关键词: MIT; Harvard; Center; Cancer; Nanotechnology

The overall goal of this U54 application is to support a highly multidisciplinary team of expert chemists, engineers, biologists, material scientists and clinicians to develop and rapidly translate new nanotechnologies to better diagnose and treat cancer in the clinic. This team formed a Center for Cancer Nanotechnology Excellence (CCNE) in 2004 and over the past 5 years has shown extraordinary productivity through its integrated research programs and shared resources. The primary team includes investigators from Massachusetts Institute of Technology (MIT), Harvard Medical School (HMS), Massachusetts General Hospital (MGH) and Brigham and Women's Hospital (BWH) and Harvard Faculty of Arts and Sciences (FAS). The CCNE thus effectively bridges programs in basic sciences at two Universities (MIT and Harvard) and clinical programs at leading Hospitals (MGH and BWH). The program will continue to be headed up by Dr. Robert Langer and Dr. Ralph Weissleder as Co-Pls. Dr. Langer is Institute Professor at MIT and member of the Koch Institute for Integrative Cancer Research at MIT (Kl). Dr. Weissleder is a Professor at Harvard Medical School, the Director of the Center for Systems Biology at MGH, a practicing clinician at MGH and a member of the Dana Farber Harvard Cancer Center. Public Health Relevance: With recent advances in nanotechnology and the introduction of some new nanomaterials into clinical trials, a myriad of opportunities are available to advance medical science and disease treatment. The translational goal is now to better control and manipulate emerging new materials by precisely configuring molecular structures, adding biological functionalities, decreasing or eliminating toxicities, and creating supramolecular

U54应用程序的总体目标是支持一个由专家化学家、工程师、生物学家、材料科学家和临床医生组成的高度多学科的团队，开发并快速转化新的纳米技术，以便在临床上更好地诊断和治疗癌症。该团队于2004年成立了癌症纳米技术卓越中心(CCNE)，在过去的5年里，通过其集成的研究计划和共享的资源，该中心展示了非凡的生产力。主要团队包括来自麻省理工学院(MIT)、哈佛医学院(HMS)、麻省总医院(MGH)、布里格姆妇女医院(BWH)和哈佛大学文理学院(FAS)的研究人员。因此，CCNE有效地连接了两所大学(麻省理工学院和哈佛大学)的基础科学课程和顶尖医院(麻省理工学院和波士顿大学)的临床课程。该项目将继续由罗伯特·兰格博士和拉尔夫·韦斯莱德博士共同负责。兰格博士是麻省理工学院的研究所教授，也是麻省理工学院科赫综合癌症研究所的成员。魏斯勒博士是哈佛医学院教授、麻省理工学院系统生物学中心主任、麻省理工学院执业临床医生和达纳·法伯哈佛癌症中心成员。 与公共卫生相关：随着纳米技术的最新进展和一些新的纳米材料进入临床试验，为促进医学科学和疾病治疗提供了无数机会。现在的翻译目标是通过精确配置分子结构、增加生物功能、减少或消除毒性以及创造超分子来更好地控制和操纵新兴的新材料